Paion AG (PA8.F) jumped in pre-market on XETRA on 03 Mar 2026 to €0.1095, a 56.43% move that placed the name among Germany’s top gainers. The PA8.F stock surge came on 7,211 shares traded versus a 2,162 average, driving market cap to roughly €781,140.00. Early session activity follows short-term momentum versus the 50-day average of €0.02 and 200-day average of €0.01. We examine valuation, technicals, catalysts, and forecasts for PA8.F stock in this pre-market update.

PA8.F stock: pre-market price action and drivers

Paion AG moved from a previous close of €0.07 to an open near €0.11, reflecting idiosyncratic buying interest. Volume hit 7,211 shares, a relative volume of 3.34, signalling heavier-than-normal retail or catalyst-driven trading. The trade range today was €0.1095 to €0.11, with the year high at €0.1795 and year low at €0.0002. This price move looks tied to momentum in thinly traded healthcare small caps and short-term positioning ahead of an earnings notice due 02 Apr 2026.

Valuation and fundamentals for PA8.F stock

Paion’s market cap stands at €781,140.00, with 7,133,700 shares outstanding. Reported trailing metrics show revenue per share €4.66 and net income per share €-0.08. Price-to-sales is extremely low at 0.02, and reported PE is negative at -1.35, reflecting recent losses. The company operates in Healthcare as a drug manufacturer focused on anesthesia and critical care, which supports long-term product optionality despite current weak profitability.

Technical view, liquidity and trading metrics

Technicals show an RSI of 52.66 and ADX 39.27, indicating a strong short-term trend. The 50-day average price is €0.02, and the 200-day average is €0.01, so the current price is well above both moving averages. Average volume is 2,162 shares, so today’s 7,211 shares represent a clear pickup in liquidity. Volatility indicators show ATR €0.03 and Bollinger band middle at €0.13, giving traders room for two-way moves.

Meyka AI grade and technical analysis for PA8.F stock

Meyka AI rates PA8.F with a score out of 100. Meyka AI rates PA8.F with a score of 63.04 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Technicals support momentum, but the grade reflects mixed fundamentals and thin liquidity. These grades are informational and not investment advice.

Catalysts, risks and sector context

Near-term catalysts include the earnings announcement scheduled for 02 Apr 2026 and any clinical or licensing updates. Healthcare sector trends show modest YTD performance, and drug manufacturers face high regulatory and development risk. Key risks for PA8.F stock include low liquidity, negative earnings, and potential dilution. Opportunities include positive clinical news or partnering deals that could re-rate the stock quickly given its small market cap.

Trading strategy and practical notes for investors

Given the volatile, thinly traded profile, traders should size positions conservatively. Stop-losses near the day low €0.1095 and profit targets tied to resistance at the year high €0.1795 are reasonable for short-term trades. Longer-term investors should watch upcoming earnings and licensing updates before adding material exposure to PA8.F stock. We link primary company filings and the XETRA listing for verification.

Final Thoughts

Key takeaways on PA8.F stock: the pre-market jump to €0.1095 on 03 Mar 2026 made Paion a top gainer on XETRA, driven by outsized volume and short-term momentum. Fundamentals remain mixed: market cap €781,140.00, negative PE, and low price-to-sales. Meyka AI’s forecast model projects monthly €0.16 (+46.12% versus €0.1095), quarterly €0.37 (+238.08%), and yearly €1.29 (+1,073.80%). Those projections imply material upside but are model-based and not guarantees. We set cautious near-term price targets at €0.20 for tactical traders and a 12-month base case target of €1.29 if catalysts materialise. Monitor liquidity, upcoming earnings on 02 Apr 2026, and sector developments. Meyka AI provides this market analysis as an AI-powered market analysis platform; these views are informational only.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.